Navigation Links
Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
Date:5/16/2008

ch as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long-term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for most patients, but can be very difficult to implement in practice. "However, the response to the gluten-free diet is poor in up to 30% of patients and dietary nonadherence is the chief cause of persistent or recurrent symptoms."(1)

About "Larazotide Acetate"

Larazotide acetate is an experimental medicine and an inhibitor of barrier dysfunction that has been shown to block abnormally increased intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through inhibitory, direct effects on gastrointestinal associated lymphoid tissue. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn's Disease. Results of the Company's first study in celiac patients are available online at: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413.x

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is located in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
2. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Nile Therapeutics Reports 2008 First Quarter Financial Results
4. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 The Board of Directors of BD ... declared a quarterly dividend of 54.5 cents per common share ... September 9, 2014. The indicated annual dividend rate is $2.18 ... is a leading medical technology company that partners with customers ... and evolving health needs. Our innovative solutions are focused on ...
(Date:7/22/2014)... Even within a phylum so full of mean little ... arthropods for its cruelty -- at least to crickets. Native ... is a most predatory sort of parasite. It swoops onto ... of larvae, and leaves its wicked brood to invade, kill ... of this would be possible without the fly,s ability to ...
(Date:7/22/2014)... Researchers from the National Institute of Standards and ... have demonstrated a new design for an atomic ... comb, or a microcomb. , The microcomb clock, ... of the new journal Optica ,* is ... microcomb, and its accurate conversion of optical frequencies ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4'Comb on a chip' powers new NIST/Caltech atomic clock design 2NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... , ... goBalto.com introduces a new project management tool - "Projects" - to help ... management tools can be awkward and cumbersome. goBalto Projects takes on project management ... time and money. , ...
... , PHOENIX and SAN CARLOS, Calif., Oct. 10 ... data today from its Phase 2 clinical trial of ... (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. ... stage investigational product candidate in clinical development for the ...
... of Toronto have developed a new "lab-on-a-chip" technique that analyses ... at risk of breast cancer much more quickly than ever ... metabolites the products of metabolized estrogen in breast ... patients compared to healthy women, and is therefore believed to ...
Cached Biology Technology:goBalto Introduces Web-based Solution to Manage Drug-development Collaborations 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 2Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 3Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix 4New lab-on-a-chip technique developed at U of T 2
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... a professor of entomology and cooperating faculty ... the University of California, Riverside, has been awarded the ... of Chemical Ecology ( ISCE ). , Awarded first ... the society,s highest honor. It is awarded annually to ... the study of chemicals that mediate interactions between living ...
(Date:7/21/2014)... to monitor seals, every movement, researchers have shown for ... to offshore wind farms and pipelines. Those man-made structures ... according to a study published in the Cell Press ... , "I was shocked when I first saw the ... Shoal," an offshore wind farm in the United Kingdom, ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... the egg genome? Researchers have answered a similarly vexing ... of long stretches of repeated DNA in the human genome ... published online by Nature Genetics on October 7, ... the human genome that are partly responsible for both disease ...
... CITY, Utah - Mario R. Capecchi, Ph.D., distinguished professor ... Utahs Eccles Institute of Human Genetics and a Howard ... Prize in Physiology or Medicine. The announcement was ... Karolinska Institute, in Stockholm, Sweden. The prize recognizes Capecchis ...
... of Cincinnati (UC) radiologists have developed a new ... eases diagnosis of venous diseases. Multi-detector computed ... three-dimensional images of arteries, the vessels which carry ... blood throughout the body. Veins, smaller vessels that ...
Cached Biology News:Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3New thoracic imaging approach can pinpoint underlying venous problems 2
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
Biology Products: